Vimarsana.com

Latest Breaking News On - Emma earl freddy crossley - Page 4 : vimarsana.com

MaxCyte to Participate in Baird Global Healthcare Conference

ROCKVILLE, Md., Sept. 05, 2023 -- MaxCyte, Inc., , a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as...

United-kingdom
David-deuchler
Rupert-dearden
Emma-earl-freddy-crossley
Panmure-gordon
Mary-jane-elliott
Chris-welsh
Nasdaq
Maxcyte-inc
Twitter
Gilmartin-group
Linkedin

MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance

MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United-kingdom
Panmure-gordon
Mary-jane-elliott
David-deuchler
Emma-earl-freddy-crossley
Rupert-dearden
Vittoria-biotherapeutics
Doug-doerfler
Chris-welsh
Lyell-immunopharma
Exchange-commission-on
Linkedin

MaxCyte Signs Strategic Platform License with Prime

Prime Medicine to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to advance their innovative Prime Editing technology and develop a...

United-kingdom
David-deuchler
Mary-jane-elliott
Panmure-gordon
Emma-earl-freddy-crossley
Doug-doerfler
Rupert-dearden
Chris-welsh
Nasdaq
Twitter
Maxcyte-inc
Medicine-inc

MaxCyte Signs Strategic Platform License with Lyell Immunopharma

Lyell Immunopharma to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform in its T cell product candidates targeting solid tumors. ROCKVILLE, Md., July 06, 2023 --...

United-kingdom
Doug-doerfler
Chris-welsh
David-deuchler
Lyell-immunopharma
Emma-earl-freddy-crossley
Rupert-dearden
Mary-jane-elliott
Panmure-gordon
Nasdaq
Twitter
Linkedin

MaxCyte Signs Strategic Platform License with Lyell Immunopharma

Lyell Immunopharma to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform in its T cell product candidates targeting solid tumors. ROCKVILLE, Md.

United-kingdom
Chris-welsh
Rupert-dearden
Panmure-gordon
Mary-jane-elliott
Doug-doerfler
Lyell-immunopharma
Emma-earl-freddy-crossley
David-deuchler
Linkedin
Lyell-immunopharma-inc
Maxcyte-inc

MaxCyte to Participate in Upcoming Investor Conferences

ROCKVILLE, Md., June 01, 2023 -- MaxCyte, Inc., a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well... | June 1, 2023

United-kingdom
Chris-welsh
Rupert-dearden
David-deuchler
Mary-jane-elliott
Emma-earl-freddy-crossley
Panmure-gordon
William-blair
Consilium-strategic-communications
Twitter
Nasdaq
Gilmartin-group

MaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023

ROCKVILLE, Md., April 12, 2023 -- MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization... | April 12, 2023

United-kingdom
Rupert-dearden
Emma-earl-freddy-crossley
David-deuchler
Panmure-gordon
Maxcyte-inc
Nasdaq
Twitter
Linkedin
Gilmartin-group
Flow-electroporation
Cyte-contacts

MaxCyte Appoints Douglas Swirsky as Chief Financial Officer

ROCKVILLE, Md., March 27, 2023 -- MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization... | March 27, 2023

United-kingdom
Douglasj-swirsky
Mary-jane-elliott
Ron-holtz
David-deuchler
Rupert-dearden
Panmure-gordon
Chris-welsh
Doug-doerfler
Douglas-swirsky
Emma-earl-freddy-crossley
Board-of-cellectar-biosciences-inc

vimarsana © 2020. All Rights Reserved.